BLPH
Income statement / Annual
Last year (2022), Bellerophon Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2022, Bellerophon Therapeutics, Inc.'s net income was -$19.83 M.
See Bellerophon Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$65,000.00 |
$102,000.00 |
$147,000.00 |
$348,000.00 |
$362,000.00 |
$373,000.00 |
$400,000.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
-$65,000.00 |
-$102,000.00 |
-$147,000.00 |
-$348,000.00 |
-$362,000.00 |
-$373,000.00 |
-$400,000.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$16.30 M
|
$13.02 M
|
$17.89 M
|
$11.03 M
|
$20.26 M
|
$17.85 M
|
$16.65 M
|
$33.37 M
|
$45.98 M
|
$52.99 M
|
| General & Administrative
Expenses |
$6.02 M
|
$7.15 M
|
$8.39 M
|
$6.44 M
|
$7.62 M
|
$6.75 M
|
$7.11 M
|
$14.87 M
|
$0.00
|
$9.01 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$6.02 M
|
$7.15 M
|
$8.39 M
|
$6.44 M
|
$7.62 M
|
$6.75 M
|
$7.11 M
|
$14.87 M
|
$13.78 M
|
$9.01 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
-$674,000.00 |
$27.88 M |
$24.60 M |
$23.76 M |
$48.24 M |
$0.00 |
$0.00 |
| Operating Expenses |
$22.38 M |
$20.16 M |
$26.28 M |
$17.47 M |
$27.88 M |
$24.60 M |
$23.76 M |
$46.57 M |
$59.75 M |
$62.00 M |
| Cost And Expenses |
$22.38 M |
$20.16 M |
$26.28 M |
$17.47 M |
$27.88 M |
$24.60 M |
$23.76 M |
$46.57 M |
$59.75 M |
$62.00 M |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$378,000.00 |
$184,000.00 |
$95,000.00 |
$109,000.00 |
$79,000.00 |
$0.00 |
| Interest Expense |
$135,000.00 |
$5,000.00 |
$250,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$65,000.00
|
$102,000.00
|
$147,000.00
|
$348,000.00
|
$362,000.00
|
$373,000.00
|
$400,000.00
|
$377,000.00
|
$388,000.00
|
$429,000.00
|
| EBITDA |
-$22.18 M
|
-$20.16 M
|
-$26.71 M
|
-$14.72 M
|
-$2.26 M
|
-$54.45 M
|
-$23.85 M
|
-$46.08 M
|
-$59.37 M
|
-$61.57 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$136,000.00
|
$605,000.00
|
-$577,000.00
|
$2.41 M
|
$25.26 M
|
-$30.22 M
|
-$495,000.00
|
$402,000.00
|
$79,000.00
|
$0.00
|
| Income Before Tax |
-$22.25 M |
-$19.56 M |
-$26.85 M |
-$15.07 M |
-$2.63 M |
-$54.82 M |
-$24.25 M |
-$46.46 M |
-$59.67 M |
-$62.00 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$2.42 M |
-$1.80 M |
-$2.13 M |
-$1.80 M |
-$5.44 M |
$29.85 M |
-$438,000.00 |
$1.18 M |
$0.00 |
$0.00 |
| Net Income |
-$19.83 M |
-$17.76 M |
-$24.73 M |
-$13.27 M |
$2.81 M |
-$54.82 M |
-$23.81 M |
-$46.46 M |
-$59.67 M |
-$62.00 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-2.08 |
-1.87 |
-3.17 |
-2.95 |
0.65 |
-21.11 |
-23.72 |
-56.81 |
-5.01 |
-4.8 |
| EPS Diluted |
-2.08 |
-1.87 |
-3.17 |
-2.95 |
0.65 |
-21.11 |
-23.72 |
-56.81 |
-5.01 |
-4.8 |
| Weighted Average Shares
Out |
$9.55 M
|
$9.50 M
|
$7.80 M
|
$4.50 M
|
$4.34 M
|
$2.60 M
|
$1.00 M
|
$817,850.00
|
$11.91 M
|
$12.91 M
|
| Weighted Average Shares
Out Diluted |
$9.55 M
|
$9.50 M
|
$7.80 M
|
$4.50 M
|
$4.34 M
|
$2.60 M
|
$1.00 M
|
$817,850.00
|
$11.91 M
|
$12.91 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
